Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.

Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN.

J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.

2.

Remodeling of the methylation landscape in breast cancer metastasis.

Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, Chan TA.

PLoS One. 2014 Aug 1;9(8):e103896. doi: 10.1371/journal.pone.0103896. eCollection 2014.

3.

The mutational landscape of adenoid cystic carcinoma.

Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, Leversha MA, Rice CE, Singh B, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Gross BE, Liang Y, Sinha R, Peng L, Raphael BJ, Turcan S, Gong Y, Schultz N, Kim S, Chiosea S, Shah JP, Sander C, Lee W, Chan TA.

Nat Genet. 2013 Jul;45(7):791-8. doi: 10.1038/ng.2643. Epub 2013 May 19.

4.

Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis.

Pencheva N, Tran H, Buss C, Huh D, Drobnjak M, Busam K, Tavazoie SF.

Cell. 2012 Nov 21;151(5):1068-82. doi: 10.1016/j.cell.2012.10.028. Epub 2012 Nov 8.

5.

Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma.

Fury MG, Drobnjak M, Sima CS, Asher M, Shah J, Lee N, Carlson D, Wendel HG, Pfister DG.

Head Neck. 2011 Sep;33(9):1340-5. doi: 10.1002/hed.21621. Epub 2010 Nov 10.

PMID:
21837706
6.

PIK3CA mutation associates with improved outcome in breast cancer.

Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME.

Clin Cancer Res. 2009 Aug 15;15(16):5049-59. doi: 10.1158/1078-0432.CCR-09-0632. Epub 2009 Aug 11.

7.

Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.

Shukla-Dave A, Hricak H, Ishill N, Moskowitz CS, Drobnjak M, Reuter VE, Zakian KL, Scardino PT, Cordon-Cardo C.

Clin Cancer Res. 2009 Jun 1;15(11):3842-9. doi: 10.1158/1078-0432.CCR-08-2453. Epub 2009 May 12.

8.

Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer.

Shukla-Dave A, Hricak H, Ishill NM, Moskowitz CS, Drobnjak M, Reuter VE, Zakian KL, Scardino PT, Cordon-Cardo C.

Radiology. 2009 Mar;250(3):803-12. doi: 10.1148/radiol.2503080473.

9.

Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence.

Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, Scardino PT, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):62-9.

PMID:
17707266
10.

Prognostic significance of p27Kip1 expression in bladder cancer.

Rabbani F, Koppie TM, Charytonowicz E, Drobnjak M, Bochner BH, Cordon-Cardo C.

BJU Int. 2007 Aug;100(2):259-63. Epub 2007 Jun 6.

11.

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.

Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK.

Clin Cancer Res. 2005 May 15;11(10):3836-45.

12.

Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.

Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, Gonen M, Schwartz GK.

Clin Cancer Res. 2005 May 1;11(9):3296-302.

13.

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA.

Mol Cancer Ther. 2004 Aug;3(8):921-32.

14.

Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo.

Richon VM, Zhou X, Secrist JP, Cordon-Cardo C, Kelly WK, Drobnjak M, Marks PA.

Methods Enzymol. 2004;376:199-205. Review. No abstract available.

PMID:
14975307
15.

p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer.

Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, Di Como CJ.

Clin Cancer Res. 2003 Nov 15;9(15):5642-51.

16.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88.

17.

Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients.

Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B, Zeleniuch-Jacquotte A, Polsky D, Ferrara J, Perez-Soler R, Cordon-Cardo C, Pagano M, Osman I.

Clin Cancer Res. 2003 Jul;9(7):2613-9.

18.

A multigenic program mediating breast cancer metastasis to bone.

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J.

Cancer Cell. 2003 Jun;3(6):537-49.

19.

HDM2 protein overexpression and prognosis in primary malignant melanoma.

Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, Cordon-Cardo C, Osman I.

J Natl Cancer Inst. 2002 Dec 4;94(23):1803-6.

PMID:
12464652
20.

Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.

Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB.

Clin Cancer Res. 2002 Oct;8(10):3226-31.

21.

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N.

Clin Cancer Res. 2002 May;8(5):986-93.

22.

The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147.

Ladanyi M, Antonescu CR, Drobnjak M, Baren A, Lui MY, Golde DW, Cordon-Cardo C.

Am J Pathol. 2002 Apr;160(4):1215-21.

23.

Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.

Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI.

Clin Cancer Res. 2002 Mar;8(3):679-83.

24.

p63 expression profiles in human normal and tumor tissues.

Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C.

Clin Cancer Res. 2002 Feb;8(2):494-501.

25.

HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.

Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C.

Clin Cancer Res. 2001 Sep;7(9):2643-7.

26.

Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.

Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA.

Clin Cancer Res. 2001 Apr;7(4):962-70.

27.

Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model.

Roque M, Cordon-Cardo C, Fuster V, Reis ED, Drobnjak M, Badimon JJ.

Atherosclerosis. 2000 Dec;153(2):315-22.

PMID:
11164420
28.

Apoptosis, proliferation, and p27 expression during vessel wall healing: time course study in a mouse model of transluminal femoral artery injury.

Reis ED, Roqué M, Cordon-Cardo C, Drobnjak M, Fuster V, Badimon JJ.

J Vasc Surg. 2000 Nov;32(5):1022-9.

29.

Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone.

Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C.

Clin Cancer Res. 2000 May;6(5):1891-5.

30.

Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.

Simak R, Capodieci P, Cohen DW, Fair WR, Scher H, Melamed J, Drobnjak M, Heston WD, Stix U, Steiner G, Cordon-Cardo C.

Histol Histopathol. 2000 Apr;15(2):365-74. doi: 10.14670/HH-15.365.

PMID:
10809354
31.

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence.

Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI.

J Natl Cancer Inst. 1999 Nov 3;91(21):1869-76.

PMID:
10547394
32.

Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.

Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C.

Clin Cancer Res. 1999 Aug;5(8):2082-8.

33.

Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization.

Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, Charytonowicz E, Dalbagni G, Cordon-Cardo C.

J Natl Cancer Inst. 1999 May 19;91(10):874-81.

PMID:
10340908
34.

Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival.

Orlow I, Drobnjak M, Zhang ZF, Lewis J, Woodruff JM, Brennan MF, Cordon-Cardo C.

J Natl Cancer Inst. 1999 Jan 6;91(1):73-9.

PMID:
9890173
35.

Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.

Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI.

J Natl Cancer Inst. 1998 Sep 2;90(17):1284-91.

PMID:
9731735
36.

Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.

Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF.

Cancer Res. 1997 Apr 1;57(7):1217-21.

37.

Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas.

Karpeh MS, Brennan MF, Cance WG, Woodruff JM, Pollack D, Casper ES, Dudas ME, Latres E, Drobnjak M, Cordon-Cardo C.

Br J Cancer. 1995 Oct;72(4):986-91.

38.

Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line.

Rosenfeld MR, Meneses P, Dalmau J, Drobnjak M, Cordon-Cardo C, Kaplitt MG.

Neurology. 1995 Aug;45(8):1533-9.

PMID:
7644054
39.

Expression of c-kit and kit ligand proteins in normal human tissues.

Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C.

J Histochem Cytochem. 1994 Nov;42(11):1417-25.

PMID:
7523489
40.

Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas.

Latres E, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, Woodruff JM, Cordon-Cardo C.

Am J Pathol. 1994 Aug;145(2):345-55.

41.

Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas.

Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, Brennan MF, Cordon-Cardo C.

J Natl Cancer Inst. 1994 Apr 6;86(7):549-54.

PMID:
8133539
42.

Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.

Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ.

Cancer Res. 1994 Feb 1;54(3):794-9.

43.

P53 and rb alterations in primary breast-carcinoma - correlation with hormone receptor expression and lymph-node metastases.

Drobnjak M, Cote R, Saad A, Drudis T, Fuks Z, Cordoncardo C.

Int J Oncol. 1993 Feb;2(2):173-8.

PMID:
21573532
44.

Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.

Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M.

Cancer Res. 1991 Dec 1;51(23 Pt 1):6372-80.

45.

Accuracy of routine flow-cytometric bitmap selection for three leukocyte populations.

Sucić M, Kolevska T, Kopjar B, Kosanović M, Drobnjak M, Zalud I, Marusić M.

Cytometry. 1989 Jul;10(4):442-7.

46.

[Terminal deoxynucleotidyl transferase--a marker for lymphatic neoplasms].

Drobnjak M.

Lijec Vjesn. 1989 Mar;111(3):63-6. Croatian.

PMID:
2747406

Supplemental Content

Loading ...
Support Center